Helsinn Out-Licenses China Rights for Cancer Care Drug to MundiPharma

Helsinn, a Swiss pharma focused on supportive cancer care, out-licensed China marketing and distribution rights for a appetite-enhancing drug to Mundipharma, a UK company. The drug, anamorelin, is a novel oral ghrelin receptor agonist currently completing clinical trials as a treatment for cancer anorexia-cachexia in patients suffering from non-small cell lung cancer. Mundipharma will have exclusive rights to anamorelin in China, Hong Kong and Macao, while Helsinn will retain rights elsewhere and be responsible for China approval. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.